Literature DB >> 33421863

The effect of smartphone-based monitoring and treatment on the rate and duration of psychiatric readmission in patients with unipolar depressive disorder: The RADMIS randomized controlled trial.

Morten Lindbjerg Tønning1, Maria Faurholt-Jepsen2, Mads Frost3, Klaus Martiny2, Nanna Tuxen2, Nicole Rosenberg2, Jonas Busk4, Ole Winther5, Sigurd Arne Melbye2, Daniel Thaysen-Petersen6, Kate Andreasson Aamund7, Lizzie Tolderlund7, Jakob Eyvind Bardram8, Lars Vedel Kessing2.   

Abstract

BACKGROUND: Patients with unipolar depressive disorder are frequently hospitalized, and the period following discharge is a high-risk-period. Smartphone-based treatments are receiving increasing attention among researchers, clinicians, and patients. We aimed to investigate whether a smartphone-based monitoring and treatment system reduces the rate and duration of readmissions, more than standard treatment, in patients with unipolar depressive disorder following hospitalization.
METHODS: We conducted a pragmatic, investigator-blinded, randomized controlled trial. The intervention group received a smartphone-based monitoring and treatment system in addition to standard treatment. The system allowed patients to self-monitor symptoms and access psycho-educative information and cognitive modules. The patients were allocated a study-nurse who, based on the monitoring data, guided and supported them. The control group received standard treatment. The trial lasted six months, with outcome assessments at 0, 3, and 6 months.
RESULTS: We included 120 patients with unipolar depressive disorder (ICD-10). Intention-to-treat analyses showed no statistically significant differences in time to readmission (Log-Rank p=0.9) or duration of readmissions (B=-16.41,95%CI:-47.32;25.5,p=0.3) (Primary outcomes). There were no differences in clinically rated depressive symptoms (p=0.6) or functioning (p=0.1) (secondary outcomes). The intervention group had higher levels of recovery (B=7,29, 95%CI:0.82;13,75,p=0.028) and a tendency towards higher quality of life (p=0.07), wellbeing (p=0,09) satisfaction with treatment (p=0.05) and behavioral activation (p=0.08) compared with the control group (tertiary outcomes). LIMITATIONS: Patients and study-nurses were unblinded to allocation.
CONCLUSIONS: We found no effect of the intervention on primary or secondary outcomes. In tertiary outcomes, patients in the intervention group reported higher levels of recovery compared to the control group.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Depression; Intervention; Randomized controlled trial; Smartphone, Technology; Unipolar depressive disorder

Mesh:

Year:  2020        PMID: 33421863     DOI: 10.1016/j.jad.2020.12.141

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  4 in total

1.  The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality.

Authors:  John Torous; Sandra Bucci; Imogen H Bell; Lars V Kessing; Maria Faurholt-Jepsen; Pauline Whelan; Andre F Carvalho; Matcheri Keshavan; Jake Linardon; Joseph Firth
Journal:  World Psychiatry       Date:  2021-10       Impact factor: 49.548

Review 2.  Human Support in App-Based Cognitive Behavioral Therapies for Emotional Disorders: Scoping Review.

Authors:  Emily E Bernstein; Hilary Weingarden; Emma C Wolfe; Margaret D Hall; Ivar Snorrason; Sabine Wilhelm
Journal:  J Med Internet Res       Date:  2022-04-08       Impact factor: 7.076

3.  Developing "MinDag" - an app to capture symptom variation and illness mechanisms in bipolar disorder.

Authors:  Thomas D Bjella; Margrethe Collier Høegh; Stine Holmstul Olsen; Sofie R Aminoff; Elizabeth Barrett; Torill Ueland; Romain Icick; Ole A Andreassen; Mari Nerhus; Henrik Myhre Ihler; Marthe Hagen; Cecilie Busch-Christensen; Ingrid Melle; Trine Vik Lagerberg
Journal:  Front Med Technol       Date:  2022-07-22

4.  Efficacy of Smartphone Apps in Patients With Depressive Disorders: A Systematic Review.

Authors:  Alba Hernández-Gómez; María José Valdés-Florido; Guillermo Lahera; Nelson Andrade-González
Journal:  Front Psychiatry       Date:  2022-08-12       Impact factor: 5.435

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.